ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Danaher’s Acquisition of Integrated DNA Technologies – Global Legal Chronicle (press release)

Continue reading

2018-03-16 Michael Zand NEWS

Dr. Plimack on the Growth of Immunotherapy in Bladder Cancer – OncLive

OncLiveDr. Plimack on the Growth of Immunotherapy in Bladder CancerOncLiveElizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the growth of immunotherapy for the treatment of patients with bladder ca… Continue reading

2018-03-15 Michael Zand NEWS

Solid Biosciences reveals upgraded clinical hold for gene therapy – BioPharma Dive

Solid Biosciences reveals upgraded clinical hold for gene therapyBioPharma DiveSolid Biosciences Inc. announced that the Food and Drug Administration has placed its Phase 1/2 Duchenne Muscular Dystrophy (DMD) trial on full clinical hold weeks after the… Continue reading

2018-03-15 Michael Zand NEWS

Expert Highlights Immunotherapy Success in GU Cancers – OncLive

OncLiveExpert Highlights Immunotherapy Success in GU CancersOncLiveThe landscape of genitourinary (GU) malignancies is rapidly evolving, with promising immunotherapy breakthroughs in renal cell carcinoma (RCC) and urothelial carcinoma. The phase III ra… Continue reading

2018-03-15 Michael Zand NEWS

Clearing clumps of protein in aging neural stem cells boosts their activity – Science Daily

Danaher’s Acquisition of Integrated DNA Technologies
Global Legal Chronicle (press release)
Paul Hastings LLP is serving as legal counsel to Integrated DNA Technologies, a privately-held life sciences company, in connection with a definitive agreement under which Danaher Corporation (NYSE: DHR) will acquire IDT. Danaher Corporation (NYSE: DHR …

Continue reading

2018-03-15 Michael Zand NEWS

Cancer immunotherapy company Arcus Biosciences up 14% in IPO – San Francisco Chronicle


Science Daily

Clearing clumps of protein in aging neural stem cells boosts their activity
Science Daily
As the cells age, they become less proficient at disposing of these protein aggregates, and their ability to respond readily to “make new neurons” signals wanes. Restoring the ability of the lysosomes to function normally rejuvenates the cells’ ability …
Aging neural stem cells struggle to take out the trash, say Stanford researchersScope (blog)

all 3 news articles »

Continue reading

2018-03-15 Michael Zand NEWS

Aging neural stem cells struggle to take out the trash, say Stanford researchers – Scope (blog)

Scope (blog)Aging neural stem cells struggle to take out the trash, say Stanford researchersScope (blog)Lately, taking out the trash has been kind of difficult at my house. Seemingly never-ending snowfall this winter (I live in Montana) has left some d… Continue reading

2018-03-15 Michael Zand NEWS

Aging neural stem cells struggle to take out the trash, say Stanford researchers – Scope (blog)

Scope (blog)Aging neural stem cells struggle to take out the trash, say Stanford researchersScope (blog)Lately, taking out the trash has been kind of difficult at my house. Seemingly never-ending snowfall this winter (I live in Montana) has left some d… Continue reading

2018-03-15 Michael Zand NEWS
  • 1
  • …
  • 393
  • 394
  • 395
  • 396
  • 397
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

San Francisco Chronicle

Cancer immunotherapy company Arcus Biosciences up 14% in IPO
San Francisco Chronicle
Arcus Biosciences Founder and CEO Terry Rosen, right, is applauded as he rings a ceremonial bell when his company’s IPO begins trading on the floor of the New York Stock Exchange, Thursday, March 15, 2018. (AP Photo/Richard Drew). Arcus Biosciences …

and more »